Although cell transplantation can rescue motor defects in Parkinson's disease (PD) models,
whether and how grafts functionally repair damaged neural circuitry in the adult brain is not …

Cell replacement is currently being explored as a therapeutic approach for
neurodegenerative disease. Using stem cells as a source, transplantable progenitors can …

A cell-based therapy for the replacement of dopaminergic neurons has been a long-term
goal in Parkinson's disease research. Here, we show that autologous engraftment of A9 …

Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by a
progressive and extensive loss of dopaminergic (DA) neurons in the substantia nigra pars …

Dopamine (DA) neurons derived from human embryonic stem cells (hESCs) are a promising
unlimited source of cells for cell replacement therapy in Parkinson's disease (PD). A number …

Neural stem cells (NSCs) possess high potencies of self-renewal and neuronal
differentiation. We explored here whether transplantation of human NSCs cloned by v-myc …

Current therapeutic approaches for Parkinson's disease (PD) provide symptomatic relief but
none of them change the course of disease. There is therefore a clear need for regenerative …

Motor dysfunctions in Parkinson's disease are considered to be primarily due to the
degeneration of dopaminergic neurons in the substantia nigra pars compacta …

In Parkinson's disease (PD), the main pathology is a loss of nigrostriatal dopamine (DA)
neurons. Clinical trials with intrastriatal transplantation of human embryonic mesencephalic …

Human embryonic stem cells (hESCs) may potentially serve as a renewable source of cells
for transplantation. In Parkinson's disease, hESC‐derived dopaminergic (DA) neurons may …